Congratulations to Amicus Therapeutics for their European Commission approval for Pombiliti™ in patients with Late-Onset Pompe Disease. We applaud Amicus and are proud to have contributed to their cold chain over the last seven years with full validation master planning and transport simulation.
Today, four leading life science companies—Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies—announce their unification...
read Details
Modality Solutions is proud to announce the launch of our new Greenwood Lab—a state-of-the-art...
read Details
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read Details
